The new financing is Series G Convertible Preferred, so until conversion Aldrich still largest stockholder. However, by Aldrich stepping down and co. adding a director most probably associated with AR Partners, Dr. Andrey Semechkin effectively has control of the company. With Aspire 2M, I estimate company can last another 10-11 months without new financing assuming tight cost control. However, if Lifeline Skin care(SC) sales takes off the current burn rate may reduce substantially. Therefore reducing the need for new financing. Rough estimate of Lifeline SC gross margin is 55-65%. Recent reviews of SC have been very positive. With the possibility of Lifeline Cell (gross margin 60-65%) sales picking up, cash flow the co. may be sufficient to fund its research activities in 12-14 months. That why it is so important to see revenue figures for the 4Q.